Examining BRAF-Inhibitor Resistance Offers Few Clues in Melanoma Treatment
May 31st 2015Due to the genetic heterogeneity observed in tumors of melanoma patients who developed resistance to BRAF inhibitors, assessing mechanisms of resistance has minimal potential to inform further treatment decisions.
New Targeted Treatment IMMU-130 for Patients With Metastatic Colon Cancer
May 29th 2015New data suggests that an experimental targeted therapy known as IMMU-130 may be effective in controlling drug-resistant metastatic colorectal cancer (mCRC) in patients previously treated with irinotecan-containing chemotherapy regimens.